Logo image of CTEV

CLARITEV CORP (CTEV) Stock Fundamental Analysis

NYSE:CTEV - New York Stock Exchange, Inc. - US62548M2098 - Common Stock - Currency: USD

39.83  +2.72 (+7.33%)

Fundamental Rating

2

Taking everything into account, CTEV scores 2 out of 10 in our fundamental rating. CTEV was compared to 36 industry peers in the Health Care Technology industry. CTEV may be in some trouble as it scores bad on both profitability and health. CTEV does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

CTEV had negative earnings in the past year.
CTEV had a positive operating cash flow in the past year.
In the past 5 years CTEV reported 4 times negative net income.
In the past 5 years CTEV always reported a positive cash flow from operatings.
CTEV Yearly Net Income VS EBIT VS OCF VS FCFCTEV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 -500M -1B -1.5B

1.2 Ratios

CTEV has a Return On Assets of -23.16%. This is comparable to the rest of the industry: CTEV outperforms 41.67% of its industry peers.
CTEV has a Return On Equity of -7942.40%. This is amonst the worse of the industry: CTEV underperforms 86.11% of its industry peers.
CTEV's Return On Invested Capital of 1.23% is fine compared to the rest of the industry. CTEV outperforms 77.78% of its industry peers.
The Average Return On Invested Capital over the past 3 years for CTEV is below the industry average of 6.38%.
Industry RankSector Rank
ROA -23.16%
ROE -7942.4%
ROIC 1.23%
ROA(3y)-13.68%
ROA(5y)-9.22%
ROE(3y)-665.39%
ROE(5y)-402.43%
ROIC(3y)2.41%
ROIC(5y)N/A
CTEV Yearly ROA, ROE, ROICCTEV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

1.3 Margins

With an excellent Operating Margin value of 8.20%, CTEV belongs to the best of the industry, outperforming 83.33% of the companies in the same industry.
CTEV's Operating Margin has declined in the last couple of years.
With a decent Gross Margin value of 74.15%, CTEV is doing good in the industry, outperforming 77.78% of the companies in the same industry.
In the last couple of years the Gross Margin of CTEV has declined.
Industry RankSector Rank
OM 8.2%
PM (TTM) N/A
GM 74.15%
OM growth 3Y-33.57%
OM growth 5Y-22.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.14%
GM growth 5Y-2.61%
CTEV Yearly Profit, Operating, Gross MarginsCTEV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

2

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so CTEV is destroying value.
Compared to 1 year ago, CTEV has about the same amount of shares outstanding.
The number of shares outstanding for CTEV has been reduced compared to 5 years ago.
The debt/assets ratio for CTEV is higher compared to a year ago.
CTEV Yearly Shares OutstandingCTEV Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 200M 400M 600M
CTEV Yearly Total Debt VS Total AssetsCTEV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B

2.2 Solvency

CTEV has an Altman-Z score of -0.31. This is a bad value and indicates that CTEV is not financially healthy and even has some risk of bankruptcy.
CTEV has a Altman-Z score of -0.31. This is comparable to the rest of the industry: CTEV outperforms 44.44% of its industry peers.
CTEV has a Debt/Equity ratio of 310.26. This is a high value indicating a heavy dependency on external financing.
CTEV has a worse Debt to Equity ratio (310.26) than 86.11% of its industry peers.
Industry RankSector Rank
Debt/Equity 310.26
Debt/FCF N/A
Altman-Z -0.31
ROIC/WACC0.18
WACC6.82%
CTEV Yearly LT Debt VS Equity VS FCFCTEV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 1B 2B 3B 4B 5B

2.3 Liquidity

CTEV has a Current Ratio of 1.02. This is a normal value and indicates that CTEV is financially healthy and should not expect problems in meeting its short term obligations.
CTEV has a Current ratio of 1.02. This is in the lower half of the industry: CTEV underperforms 72.22% of its industry peers.
A Quick Ratio of 1.02 indicates that CTEV should not have too much problems paying its short term obligations.
CTEV's Quick ratio of 1.02 is on the low side compared to the rest of the industry. CTEV is outperformed by 72.22% of its industry peers.
Industry RankSector Rank
Current Ratio 1.02
Quick Ratio 1.02
CTEV Yearly Current Assets VS Current LiabilitesCTEV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

3

3. Growth

3.1 Past

CTEV shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -904.03%.
The Revenue has decreased by -3.33% in the past year.
CTEV shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -1.09% yearly.
EPS 1Y (TTM)-904.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-225%
Revenue 1Y (TTM)-3.33%
Revenue growth 3Y-5.92%
Revenue growth 5Y-1.09%
Sales Q2Q%-1.36%

3.2 Future

The Earnings Per Share is expected to grow by 22.28% on average over the next years. This is a very strong growth
Based on estimates for the next years, CTEV will show a small growth in Revenue. The Revenue will grow by 2.81% on average per year.
EPS Next Y82.64%
EPS Next 2Y36.03%
EPS Next 3Y22.28%
EPS Next 5YN/A
Revenue Next Year0.16%
Revenue Next 2Y1.63%
Revenue Next 3Y2.81%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CTEV Yearly Revenue VS EstimatesCTEV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 200M 400M 600M 800M 1B
CTEV Yearly EPS VS EstimatesCTEV Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 0 -20 -40 -60 -80

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

CTEV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CTEV is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CTEV Price Earnings VS Forward Price EarningsCTEV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, CTEV is valued cheaply inside the industry as 88.89% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 10.16
CTEV Per share dataCTEV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -100 -200

4.3 Compensation for Growth

A more expensive valuation may be justified as CTEV's earnings are expected to grow with 22.28% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.03%
EPS Next 3Y22.28%

More info and screens

0

5. Dividend

5.1 Amount

CTEV does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CLARITEV CORP

NYSE:CTEV (6/16/2025, 5:47:13 PM)

39.83

+2.72 (+7.33%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)05-08 2025-05-08/bmo
Earnings (Next)07-30 2025-07-30
Inst Owners35.19%
Inst Owner ChangeN/A
Ins Owners8.14%
Ins Owner Change27.46%
Market Cap654.81M
Analysts80
Price Target31.96 (-19.76%)
Short Float %5.02%
Short Ratio4.48
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-4.46%
Min EPS beat(2)-23.58%
Max EPS beat(2)14.65%
EPS beat(4)1
Avg EPS beat(4)-387.47%
Min EPS beat(4)-1467.36%
Max EPS beat(4)14.65%
EPS beat(8)4
Avg EPS beat(8)-184.38%
EPS beat(12)5
Avg EPS beat(12)-291.62%
EPS beat(16)8
Avg EPS beat(16)-195.66%
Revenue beat(2)1
Avg Revenue beat(2)-0.51%
Min Revenue beat(2)-2.88%
Max Revenue beat(2)1.86%
Revenue beat(4)1
Avg Revenue beat(4)-2.8%
Min Revenue beat(4)-6.88%
Max Revenue beat(4)1.86%
Revenue beat(8)2
Avg Revenue beat(8)-2.49%
Revenue beat(12)3
Avg Revenue beat(12)-3.1%
Revenue beat(16)6
Avg Revenue beat(16)-1.91%
PT rev (1m)44.62%
PT rev (3m)N/A
EPS NQ rev (1m)-16.37%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)0.72%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.19%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.71
P/FCF N/A
P/OCF 23.52
P/B 44.17
P/tB N/A
EV/EBITDA 10.16
EPS(TTM)-72.29
EYN/A
EPS(NY)-10.41
Fwd EYN/A
FCF(TTM)-6
FCFYN/A
OCF(TTM)1.69
OCFY4.25%
SpS56.41
BVpS0.9
TBVpS-275.47
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -23.16%
ROE -7942.4%
ROCE 1.55%
ROIC 1.23%
ROICexc 1.23%
ROICexgc 17.81%
OM 8.2%
PM (TTM) N/A
GM 74.15%
FCFM N/A
ROA(3y)-13.68%
ROA(5y)-9.22%
ROE(3y)-665.39%
ROE(5y)-402.43%
ROIC(3y)2.41%
ROIC(5y)N/A
ROICexc(3y)2.48%
ROICexc(5y)N/A
ROICexgc(3y)66.67%
ROICexgc(5y)N/A
ROCE(3y)3.05%
ROCE(5y)N/A
ROICexcg growth 3Y-40.96%
ROICexcg growth 5Y-27.14%
ROICexc growth 3Y-26.84%
ROICexc growth 5Y-14.89%
OM growth 3Y-33.57%
OM growth 5Y-22.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.14%
GM growth 5Y-2.61%
F-Score4
Asset Turnover0.18
Health
Industry RankSector Rank
Debt/Equity 310.26
Debt/FCF N/A
Debt/EBITDA 8.99
Cap/Depr 29.03%
Cap/Sales 13.63%
Interest Coverage 0.23
Cash Conversion 5.44%
Profit Quality N/A
Current Ratio 1.02
Quick Ratio 1.02
Altman-Z -0.31
F-Score4
WACC6.82%
ROIC/WACC0.18
Cap/Depr(3y)25.06%
Cap/Depr(5y)22.79%
Cap/Sales(3y)10.77%
Cap/Sales(5y)9.49%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-904.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-225%
EPS Next Y82.64%
EPS Next 2Y36.03%
EPS Next 3Y22.28%
EPS Next 5YN/A
Revenue 1Y (TTM)-3.33%
Revenue growth 3Y-5.92%
Revenue growth 5Y-1.09%
Sales Q2Q%-1.36%
Revenue Next Year0.16%
Revenue Next 2Y1.63%
Revenue Next 3Y2.81%
Revenue Next 5YN/A
EBIT growth 1Y-50.8%
EBIT growth 3Y-37.5%
EBIT growth 5Y-23.25%
EBIT Next Year144.03%
EBIT Next 3Y35.48%
EBIT Next 5YN/A
FCF growth 1Y-164.23%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-88.48%
OCF growth 3Y-35.69%
OCF growth 5Y-17.66%